The title of the article is called Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis revealed by organelle specific antibodies. The article was written by Mourelatos, Z., Adler, H., Hirano, A., Donnenfeld, H., Gonatas, J. O., and Gonatas, N. K., of the University Of Pennsylvania School Of Medicine, Philadelphia. This article describes the use of an antiserum of the sialoglycoprotein of rat cells Golgi apparatus, in the analysis of amyotrophic lateral sclerosis. The last figure in the article depicts an image from either an electron microscope or scanning microscope, discerning the degeneration of the Golgi apparatus associated with amyotrophic lateral sclerosis. This has substantiated the hypothesis that degeneration of Golgi apparatus in amyotrophic lateral sclerosis victims has functional impact on them.
We will write a custom Term Paper on Amyotrophic Lateral Sclerosis: Clinical Trial specifically for you
807 certified writers online
The guideline title is called EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. An evidence-based review with good practice points. Eur J Neurol 2005 Dec; 12(12):921-38. These guidelines seek to optimize the clinical approach to cases of amyotrophic lateral sclerosis by designing guidelines that are based on patient and provider studies outcome. This guidelines focus on patients suffering from amyotrophic lateral sclerosis together with their families. This outcome had put into consideration three main outcomes including the efficiency of ALS treatment in increasing the patient’s survival time; reducing the number and duration of hospital admissions; and promoting the quality of patient’s life. This set of guidelines depicts that amyotrophic lateral sclerosis is a terminal illness and patients suffering from this condition should be placed on palliative care. arising in the course of accomplishing them.
The clinical trial was called High Fat/High calorie Trial in Amyotrophic Lateral Sclerosis. This research was being conducted on September 2010 whereby the recruiting participants were going on at the Massachusetts General Hospital. The trial was funded by the Massachusetts General Hospital in collaboration with the Muscular Dystrophy Association. Moreover the identification number of the trial is NCT00983983. The condition of the trial is essentially Amyotrophic Lateral Sclerosis. The interventions for the trial include 3 dietary supplements. These were Oxepa, Jevity 1.5 and Jevity 1.0. The trial is in phase II safety and tolerability study of High Fat/High Calorie Versus Optimal Nutrition in subjects who were suffering from Amyotrophic Lateral Sclerosis. The subjects who were eligible for participation in the study were victims of amyotrophic lateral sclerosis who are both female and male of age 18 and above. In addition the subjects must be tolerant to any of the two form of tube feeding, which include jejunostomy tube (J-tube) and gastrotomy tube (G-tube or PEG). Recruitment of subjects was conducted at various venues in the United States. These venues include University of California, Emory University School of Medicine, Neurological Clinical trial unit of Massachusetts General Hospital, Colombia Presbyterian Medical centre, Carolina Medical centre neuromuscular/ALS-MDA Centre, Oregon Health and Science University, Drexel University, Methodist neurological institute, and University of Vermont. This clinical trial had been approached from the weight loss symptom perspective of amyotrophic lateral sclerosis (ALS). The severe weight loss symptom was proposed to be an attribute of insufficient calorie intake or an accelerated metabolism. Thus the trial was aimed at establishing the appropriate diet for Amyotrophic Lateral Sclerosis patients. Amyotrophic lateral sclerosis is a terminal disease whose patients require the services of palliative care providers in order to prolong their life and improve the quality of their lives.